<DOC>
	<DOCNO>NCT02719691</DOCNO>
	<brief_summary>This phase Ib study design evaluate safety toxicity combination Alisertib MLN0128 patient advance solid tumor expansion cohort patient previously treat metastatic TNBC .</brief_summary>
	<brief_title>Phase I Study MLN0128 MLN8237 Patients With Advanced Solid Tumors Metastatic Triple-negative Breast Cancer</brief_title>
	<detailed_description>The purpose study evaluate combination Alisertib MLN0128 patient advance solid tumor refractory standard treatment follow expansion cohort patient metastatic TNBC exploratory correlative study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<criteria>1 . Male female patient 18 year old . 2 . Dose Escalation Cohort : Patients must diagnosis histologically confirm solid tumor incurable refractory standard therapy standard therapy exist . 3 . TNBC Dose Expansion Cohort : Patients must diagnosis histologically confirm metastatic TNBC define negative estrogen receptor , progesterone receptor human epidermal growth factor 2 ( HER2 ) . Patients must receive either adjuvant first line chemotherapy metastatic disease . 4 . Dose Expansion Cohort : At least one tumor lesion amenable repeat core needle biopsy punch biopsy without unacceptable risk major procedural complication . 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; 1 . 6 . Three week 5 halflives previous systemic anticancer therapy . 7 . All acute treatmentrelated toxicity prior therapy must resolve Grade &lt; 1 prior study entry exclude alopecia . 8 . For woman : Postmenopausal least 1 year screen visit , OR Surgically sterile , OR If childbearing potential , agree practice 2 effective method contraception . For men : â€¢ Agree practice effective barrier contraception entire study treatment period 120 day last dose study drug . 9 . Patients must meet screening laboratory value . 10 . Left ventricular ejection fraction ( LVEF ) &gt; low limit normal ( LLN ) institutional standard normal measure echocardiogram ( ECHO ) multiple gated acquisition scan ( MUGA ) within 4 week prior first study drug administration . 11 . Ability swallow oral medication . 12 . Voluntary write consent must give performance study relate procedure part standard medical care , understand consent may withdraw patient time without prejudice future medical care . 13 . Patients history brain metastasis eligible study provide meet certain criterion . 1 . Other clinically significant comorbidities . 2 . Known human immunodeficiency virus infection . 3 . Radiation therapy 25 % bone marrow . 4 . Known history uncontrolled sleep apnea syndrome condition could result excessive daytime sleepiness . 5 . Systemic infection require IV antibiotic therapy within 14 day precede first dose study drug , severe infection . 6 . Known hepatitis B surface antigenpositive , know suspect active hepatitis C infection . 7 . Any serious medical psychiatric illness . 8 . Diagnosed treat another malignancy within 2 year administration first dose study drug , previously diagnose another malignancy evidence residual disease . Patients nonmelanoma skin cancer carcinoma situ type exclude undergone complete resection . 9 . Breast feeding pregnant . 10 . Manifestations malabsorption due prior gastrointestinal ( GI ) surgery , GI disease , unknown reason may alter absorption MLN0128 . In addition , patient enteric stoma also exclude . 11 . Treatment investigational product within 3 week first dose study drug . 12 . History follow within last 6 month administration first dose drug : Ischemic myocardial event , include angina require therapy artery revascularization procedure Ischemic cerebrovascular event , include transient ischemic attack artery revascularization procedure Requirement inotropic support ( exclude digoxin ) serious ( uncontrolled ) cardiac arrhythmia ( include atrial flutter/fibrillation , ventricular fibrillation ventricular tachycardia ) Placement pacemaker control rhythm New York Heart Association ( NYHA ) Class III IV heart failure Pulmonary embolism 13 . Significant active cardiovascular pulmonary disease . 14 . Treatment strong inhibitor and/or inducer cytochrome P450 ( CYP ) 3A4 , CYP2C19 CYP2C19 within 1 week precede first dose study drug . 15 . Patients receive systemic corticosteroid within 1 week administration first dose study drug . 16 . Daily chronic use proton pump inhibitor ( PPI ) and/or take PPI within 7 day receive first dose study drug 17 . For patient undergo serial tumor biopsy , know bleed diathesis history abnormal bleeding require anticoagulation therapy interrupt biopsy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>101 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>MLN0128</keyword>
	<keyword>Dual TORC1/2 Inhibitor</keyword>
	<keyword>MLN8237</keyword>
	<keyword>Aurora A inhibitor</keyword>
	<keyword>Alisertib</keyword>
	<keyword>Triple-Negative Breast Cancer</keyword>
</DOC>